Modeling enterprise risk management in operations and supply chain : a pharmaceutical firm context
Date
2018
item.page.datecreated
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The growing prevalence of disruptive influences in modern operations and supply chains has called for a systematic approach to identify risk sources and to develop predictive enterprise risk management. This imperative has become a top priority for many organizations such as the pharmaceutical industry. This paper leverages a multi-criteria decision making methodology to model enterprise risk management in a focal pharmaceutical firm operations and supply chain. Six types of risks and five strategies are considered and analyzed. Results suggest that supply chain executives attach great importance to regulation/legislation, followed by operational, and reputation risks, while financial, market, and relationship risks ranked low in importance. With respect to enterprise risk management strategies, risk reduction/mitigation was considered the best option followed by risk avoidance option. From the results, it appears that multi-criteria decision making methodology can be used to assist supply chain executives in developing a priority hierarchy for risk management strategies. It can also help the management with a step-by-step approach to identify, assess, and manage portfolio of risks that can be detrimental to their pharmaceutical supply chain performance, brand equity, profit growth, and shareholder value. © Operations and Supply Chain Management. All rights reserved.
Description
This article is not available at CUD collection. The version of scholarly record of this Article is published in Operations and Supply Chain Management (2018), available online at: http://doi.org/10.31387/oscm0300195
item.page.type
Article
item.page.format
Keywords
Multi-criteria decision, Pharmaceutical supply chain risk, Risk management strategies
Citation
Enyinda, C. I. (2018). Modeling enterprise risk management in operations and supply chain: A pharmaceutical firm context. Operations and Supply Chain Management, 11(1), 1–12. http://doi.org/10.31387/oscm0300195